Literature DB >> 6434788

The metabolism of arachidonic acid by platelets in nephrotic syndrome.

A Schieppati, P Dodesini, A Benigni, M Massazza, G Mecca, G Remuzzi, M Livio, G de Gaetano, E C Rossi.   

Abstract

The production of malondialdehyde (MDA) and thromboxane B2 (TxB2) by platelets following an arachidonic acid (AA) challenge was greater in nephrotic platelet rich plasma (PRP) than in normal PRP. The uptake of 14C-AA, and its subsequent conversion to 14C-TxB2 following a thrombin stimulus, was also greater in nephrotic than normal PRP. Normal plasma diminished the MDA production by nephrotic platelets. The addition of albumin to nephrotic PRP, or, the intravenous infusion of albumin in quantities sufficient to correct hypoalbuminemia also diminished the excessive production of prostaglandin metabolites by nephrotic platelets. The platelet aggregate ratio (PAR), which measures circulating platelet aggregates, was abnormal during the acute phase of nephrotic syndrome but reverted to normal following remission. These data indicate that hypoalbuminemia is associated with increased AA metabolism by platelets and suggest that platelet "hyperactivity" may contribute to the proclivity toward thrombosis observed in nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434788     DOI: 10.1038/ki.1984.72

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Venous thromboembolism in patients with membranous nephropathy.

Authors:  Sophia Lionaki; Vimal K Derebail; Susan L Hogan; Sean Barbour; Taewoo Lee; Michelle Hladunewich; Allen Greenwald; Yichun Hu; Caroline E Jennette; J Charles Jennette; Ronald J Falk; Daniel C Cattran; Patrick H Nachman; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-10       Impact factor: 8.237

Review 2.  Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms.

Authors:  Keattiyoat Wattanakit; Mary Cushman
Journal:  Curr Opin Pulm Med       Date:  2009-09       Impact factor: 3.155

3.  In vivo platelet activity and serum albumin concentration in nephrotic syndrome.

Authors:  F Goubran; F Maklady
Journal:  Blut       Date:  1988-07

Review 4.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

Review 5.  Platelet abnormalities in nephrotic syndrome.

Authors:  Benedicte Eneman; Elena Levtchenko; Bert van den Heuvel; Chris Van Geet; Kathleen Freson
Journal:  Pediatr Nephrol       Date:  2015-08-13       Impact factor: 3.714

6.  Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.

Authors:  G Remuzzi; L Imberti; M Rossini; C Morelli; C Carminati; G M Cattaneo; T Bertani
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

Review 7.  Hemostatic complications in renal disorders of the young.

Authors:  M Andrew; L A Brooker
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

Review 8.  Acute phase reactants as novel predictors of cardiovascular disease.

Authors:  M S Ahmed; A B Jadhav; A Hassan; Qing H Meng
Journal:  ISRN Inflamm       Date:  2012-05-06

Review 9.  Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Aram Barbaryan; Suartcha Prueksaritanond; Nasir Hussain
Journal:  Int J Nephrol       Date:  2014-04-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.